Medical Center Rodopimed EOOD

Research site

Bulgaria Ulitsa Osogovo 8, 6600 Kirdzhali, Bulgaria

4 trials recruiting
Cardiac failure · Hypertriglyceridaemia · Systemic lupus erythematosus
Adult patients

About Specializations

Medical Center Rodopimed EOOD in Kirdzhali, Bulgaria specialises in clinical trials of conditions such as Cardiac failure, Hypertriglyceridaemia, Systemic lupus erythematosus, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Rheumatology and Autoimmune Diseases

The medical center is at the forefront of research in rheumatology and autoimmune diseases, with a particular focus on Systemic Lupus Erythematosus (SLE). The center's ongoing studies aim to enhance the understanding and treatment of this complex condition.

Systemic Lupus Erythematosus (SLE)
Autoimmune Disease Management
Innovative Therapeutic Approaches

Through the investigation of novel therapies such as anifrolumab, the center is contributing to significant advancements in the management of moderate-to-severe SLE, offering hope for improved patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ulitsa Osogovo 86600 KirdzhaliBulgaria

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 11

More sites in Kirdzhali Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Bulgaria

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Systemic lupus erythematosus+3

Recruiting

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim International GmbH

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Hypertriglyceridaemia

Not recruiting

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational

Study of Plozasiran for Adults with Severe Hypertriglyceridemia

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
Sponsor:Arrowhead Pharmaceuticals Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo

Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Axial spondyloarthritis

Not recruiting

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Filgotinib
Sponsor:Alfasigma S.p.A.

Contact Research Centre

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Andexanet Alfa
Sponsor:Janssen Cilag International

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites